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BACKGROUND AND PURPOSE
The mechanism of the anti-migraine action of extracts of butterbur [Petasites hybridus (L.) Gaertn.] is unknown. Here, we inves-
tigated the ability of isopetasin, a major constituent of these extracts, to specifically target TRPA1 channel and to affect functional
responses relevant to migraine.
EXPERIMENTAL APPROACH
Single-cell calcium imaging and patch-clamp recordings in human and rodent TRPA1-expressing cells, neurogenic motor
responses in rodent isolated urinary bladder, release of CGRP from mouse spinal cord in vitro and facial rubbing in mice and
meningeal blood flow in rats were examined.
KEY RESULTS
Isopetasin induced (i) calcium responses and currents in rat/mouse trigeminal ganglion (TG) neurons and in cells expressing the
human TRPA1, (ii) substance P-mediated contractions of rat isolated urinary bladders and (iii) CGRP release from mouse dorsal
spinal cord, responses that were selectively abolished by genetic deletion or pharmacological antagonism of TRPA1 channels.
Pre-exposure to isopetasin produced marked desensitization of allyl isothiocyanate (AITC, TRPA1 channel agonist)- or capsaicin
(TRPV1 channel agonist)-evoked currents in rat TG neurons, contractions of rat or mouse bladder and CGRP release from mouse
central terminals of primary sensory neurons. Repeated intragastric administration of isopetasin attenuated mouse facial rubbing,
evoked by local AITC or capsaicin, and dilation of rat meningeal arteries by acrolein or ethanol (TRPA1 and TRPV1 channel agonists
respectively).
CONCLUSION AND IMPLICATIONS
Activation of TRPA1 channels by isopetasin results in excitation of neuropeptide-containing nociceptors, followed by marked
heterologous neuronal desensitization. Such atten uation in pain and neurogenic inflammationmay account for the anti-migraine
action of butterbur.
Abbreviations
AITC, allyl isothiocyanate; IMR90, human fetal lung fibroblasts; PAR2, proteinase activated receptor 2; SP, substance P; TG,
trigeminal ganglion
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Introduction
For hundreds of years, butterburs (Petasites), herbaceous pe-
rennial plants belonging to the Asteraceae, which includes
also Tanacetum parthenium L. (Materazzi et al., 2013), have
been used in folk medicine of northern Eurasia and America
for therapeutic purposes, including treatment of fever, respi-
ratory diseases, spasms and pain (Sutherland and Sweet,
2010). Among the many compounds contained in common
butterbur [Petasites hybridus (L.) Gaertn.] (Aydin et al., 2013),
two major constituents, petasin and isopetasin (Avula et al.,
2012), are considered responsible for the anti-migraine ef-
fects of the herbal extract (Danesch and Rittinghausen,
2003). Clinical evidence (Grossmann and Schmidramsl,
2000; Lipton et al., 2004; Pothmann and Danesch, 2005) of
beneficial action in migraine prevention has been obtained
with a preparation that contains standardized amounts (min-
imum 15%, corresponding to 7.5 mg) of petasin/isopetasin
(Avula et al., 2012; Danesch and Rittinghausen, 2003). The
collective standardization is due to the instability of petasin,
which spontaneously converts to isopetasin. Due to the
stability issue, the specific role of each sesquiterpenoid for
bioactivity has not been clearly identified.
Several hypotheses have been advanced to explain the
anti-migraine action of petasin/isopetasin, including inhibi-
tion of leukotriene synthesis in leukocytes (Thomet et al.,
2001) and of voltage-sensitive calcium channels in arterial
smooth muscle cells (Wang et al., 2001; Wang et al., 2002)
or anti-muscarinic activity (Ko et al., 2001). However, none
of these actions seems to be relevant for migraine pathophys-
iology. Despite this mechanistic uncertainty, butterbur ex-
tract is currently recommended at high levels of strength for
migraine prophylaxis (Holland et al., 2012). Petasin and its
cross-conjugated isomer, isopetasin, are eremophilane ses-
quiterpene esters of petasol and angelic acid (Supporting
Information Figure S1A). Both compounds contain electro-
philic double bonds and can potentially interact with
bionucleophiles. Nevertheless, given the disubstitution at
the β-carbon, they do not react with thiols, while giving a
negative cysteamine assay (Avonto et al., 2011).
The cation channelTRPA1 belongs to the larger family of
the TRP channels and, together with theTRPV1 andTRPV4
channels, is expressed by a sub-population of primary
sensory neurons also characterized by their dual function of
signalling pain and releasing the neuropeptides, substance P
(SP) and CGRP, which mediate neurogenic inflammation
(Nassini et al., 2012). TRPA1 channels are selectively
activated by a series of natural products, including allyl
isothiocyanate (AITC, a constituent of horseradish) and
cinnamaldehyde (a constituent of cinnamon). There is now
robust evidence that TRPA1 channels transduce pain signals
(Andersson et al., 2008; Fusi et al., 2014; Nassini et al., 2015;
Nassini et al., 2014; Trevisan et al., 2016) generated by an
unprecedented series of reactive oxygen, nitrogen and car-
bonyl species that target the channel via nucleophilic attack
of specific cysteine residues of the channels (Macpherson
et al., 2007).
A possible role of TRPA1 channels in migraine (Benemei
et al., 2014) is supported by its co-expression in the same
nociceptor subpopulation (Bhattacharya et al., 2008) with
CGRP, the neuropeptide that markedly contributes to
migraine pain (Edvinsson, 2015b; Ho et al., 2008; Miller
et al., 2016; Olesen et al., 2004; Sun et al., 2016). Furthermore,
agents known as potent headache and specific migraine trig-
gers, such as acrolein (Kunkler et al., 2011) or umbellulone
(Benemei et al., 2009), have been identified as agonists at
TRPA1 channels (Kunkler et al., 2011; Nassini et al., 2012). It
is relevant to the present study that another sesquiterpene,
the lactone, parthenolide, a major constituent of feverfew
(Tanacetum parthenium) (used for centuries for pain and head-
ache treatment; Holland et al., 2012), induces desensitization
of TRPA1 channels and of nociceptors (Materazzi et al., 2013).
Other herbal medicines used for the treatment of pain and
headaches, such as ligustilide, have been proposed to act by
targeting the TRPA1 channel (Zhong et al., 2011). Finally,
the pyrazolone derivatives, dipyrone and propyphenazone
(old analgesics with a well-established anti-migraine effect)
(Bigal et al., 2002) are poor cyclooxygenase inhibitors, while
at clinically relevant doses, they selectively antagonize the
TRPA1 channel (Nassini et al., 2015).
Given the role of electrophilic compounds for the
paradoxical induction and prevention of headache via
modulation of the activity of the TRPA1 channel (Nassini
et al., 2012; Nilius and Szallasi, 2014), we wondered if the
butterbur sesquiterpenoids could target the channel. Our
findings indicated that the petasin family of compounds
selectively targeted TRPA1 channel, leading to an initial
neuronal excitation followed by marked desensitization of
the afferent and efferent function of peptidergic nociceptors
expressing TRPA1 channel. Similar to data reported for
parthenolide, the present results suggest that the anti-
migraine action of butterbur extracts may derive from the
ability of isopetasin to evoke TRPA1-dependent desensitiza-
tion of nociceptors that mediate neurogenic inflammation.
Methods
Animals
All animal care and experimental procedures were carried out
according to the European Union (EU) guidelines and Italian
legislation (DLgs 26/2014, EU Directive application 2010/63/
EU) for animal care procedures and were approved under
University of Florence research permits #204/2012-B and
#194/2015-PR. In addition, the number of animals and inten-
sity of noxious stimuli used were the minimum necessary to
demonstrate consistent effects of the treatments used. Ani-
mal studies are reported in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015).
C57BL/6 mice (male, 20–25 g, 5 weeks; Envigo, Milan,
Italy; N = 208), littermate wild-type (Trpa1+/+, N = 35) and
TRPA1-deficient (Trpa1/; N = 50) mice (25–30 g,
5–8 weeks), generated by heterozygotes on a C57BL/6 back-
ground (B6.129P–Trpa1tm1Kykw/J; Jackson Laboratories, Bar
Harbor, ME, USA), wild-type (Trpv4+/+; N = 15) and TRPV4-
deficient (Trpv4/; N = 15) mice (25–30 g, 5–8 weeks),
generated by heterozygotes on a C57BL/6 background
(Liedtke and Friedman, 2003) and TRPV1-deficient mice
(Trpv1/; B6.129X1-Trpv1tm1Jul/J; N = 15) backcrossed with
C57BL/6 mice (Trpv1+/+; N = 15) for at least 10 generations
(Jackson Laboratories, Bar Harbor, ME, USA; 25–30 g,
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5–8 weeks) or Sprague–Dawley rats (male, 75–100 g, Envigo,
Milan, Italy; N = 73) were used.
Animals were housed in a controlled-temperature envi-
ronment, 10 per cage (mice) or five per cage (rats), with wood
shaving bedding and nesting material, maintained at 22 ± 1°
C. Animals were housed with a 12 h light/dark cycle (lights
on at 07:00 h) and fed with rodent chow (Global Diet 2018,
Harlan, Lombardy, Italy) and tap water ad libitum. Animals
were allowed to acclimatize to their housing environment
for at least 7 days prior to experimentation and to the exper-
imental room for 1 h before experiments. Behavioural exper-
iments were done in a quiet, temperature-controlled (20 to
22°C) room between 09:00 and 17:00 h and were performed
by an operator blinded to genotype and drug treatment. Ani-
mals were killed with inhaled CO2 plus 10–50% O2 under a
valid institutional animal protocol.
Cell culture and isolation of primary sensory
neurons
Naïve untransfected HEK293 cells (American Type Culture
Collection, Manassas, VA, USA; ATCC® CRL-1573™) were
cultured according to the manufacturer’s instructions.
HEK293 cells were transiently transfected with the cDNAs
(1 μg) coding for wild-type (wt-hTRPA1) or mutant 3C/K-
Q human TRPA1 (C619S, C639S, C663S, K708Q; 3C/K-Q
hTRPA1-HEK293) (both donated by D. Julius, University
of California, San Francisco, CA, USA) (Hinman et al.,
2006) using the jetPRIME transfection reagent (Poliyplus-
transfection® SA, Strasburg, France) according to the manu-
facturer’s protocol. HEK293 cells stably transfected with
cDNA for human TRPA1 (hTRPA1-HEK293, donated by A.H.
Morice, University of Hull, Hull, UK), or with cDNA for hu-
man TRPV1 (hTRPV1-HEK293, donated by M. J. Gunthorpe,
GlaxoSmithKline, Harlow, UK), or with cDNA for human
TRPV4 (hTRPV4-HEK293, donated byN.W. Bunnett, Monash
Institute of Pharmaceutical Sciences, Parkville, Australia)
were cultured as previously described (Nassini et al., 2015).
Human fetal lung fibroblasts (IMR90; American Type Culture
Collection, Manassas, VA, USA; ATCC® CCL-186™), which
express the native TRPA1 channel, were cultured in DMEM
supplemented with 10% FBS, 2 mM glutamine, 100 U
penicillin and 100 μg·mL1 streptomycin. Cells were plated
on glass coated (poly-L-lysine, 8.3 μM) coverslips and
cultured for 2–3 days before being used for recordings. For
all cell lines, the cells were used as received without further
authentication.
Primary trigeminal ganglion (TG) neurons were isolated
from adult Sprague–Dawley rats and C57BL/6 or Trpa1+/+
and Trpa1/ mice and cultured as previously described
(Materazzi et al., 2013). Briefly, TGwere bilaterally excised un-
der a dissection microscope and transferred to HBSS contain-
ing 1 mg·mL1 of trypsin plus 2 mg·mL1 of collagenase type
1A or papain, for rat or mouse ganglia, respectively, for
enzymatic digestion (30 min, 37°C). Ganglia were then
transferred to warmed DMEM containing: 10% FBS, 10%
horse serum, 2 mM L-glutamine, 100 U·mL1 penicillin
and 100 mg·mL1 streptomycin and dissociated into single
cells by several passages through a series of syringe needles
(23–25 G). Medium and ganglia cells were filtered to remove
debris and centrifuged. The pellet was suspended in DMEM
with added 100 ng·mL1 mouse-NGF and 2.5 mM cytosine-
D-arabinofuranoside free base. Neurons were then plated on
glass coverslips coated with poly-L-lysine (8.3 μM) and lam-
inin (5 μM).
Cellular recordings
Mobilization of intracellular calcium ([Ca2+]i) was measured
in untransfected or transfected HEK293 cells, in IMR90 and
in primary sensory neurons, as previously reported
(Materazzi et al., 2013). Plated cells were loaded with 5 μM
Fura-2 AM-ester (Alexis Biochemicals; Lausen, Switzerland)
added to the buffer solution (37°C) containing the follow-
ing (in mM): 2 CaCl2; 5.4 KCl; 0.4 MgSO4; 135 NaCl; 10
D-glucose; 10 HEPES and 0.1% bovine serum albumin at
pH 7.4. After loading (40 min, 37°C), cells were washed
and transferred to a chamber on the stage of an Olympus
IX81 microscope for recording. Cells were excited alter-
nately at 340 and 380 nm to indicate relative intracellular
calcium changes by the Ratio340/380 (R340/380) and recorded
with a dynamic image analysis system (XCellence Imaging
software; Olympus srl, Milan, Italy). Results are expressed
as the percentage of increase of R340/380 over the baseline
normalized to the maximum effect induced by ionomycin
(5 μM) (% Change in R340/380).
Whole-cell patch-clamp recordings were performed in
untransfected and transfected HEK293 cells and in primary
sensory neurons plated on coated coverslips as previously re-
ported (Materazzi et al., 2013). Briefly, coverslips were trans-
ferred to a recording chamber (1 mL volume), mounted on
the platform of an inverted microscope (Olympus CKX41,
Milan, Italy) and superfused at a flow rate of 2 mL·min1 with
a standard extracellular solution containing (in mM): 10
HEPES, 10 D-glucose, 147 NaCl, 4 KCl, 1 MgCl2 and 2 CaCl2
(pH adjusted to 7.4 with NaOH). Borosilicate glass electrodes
(Harvard Apparatus, Holliston, MA, USA) were pulled with a
Sutter Instruments puller (model P-87) to a final tip resistance
of 4–7 MΩ. Pipette solution used for HEK293 cells contained
(in mM): 134 K-gluconate, 10 KCl, 11 EGTA, 10 HEPES (pH
adjusted to 7.4 with KOH). When recordings were performed
on rat neurons, 5 mM CaCl2 was present in the extracellular
solution and pipette solution contained (in mM): 120 CsCl,
3 Mg2ATP, 10 BAPTA, 10 HEPES-Na (pH adjusted to 7.4
with CsOH). Data were acquired with an Axopatch 200B
amplifier (Axon Instruments, CA, USA), stored and analysed
with a pClamp 9.2 software (Axon Instruments, CA, USA).
All the experiments were carried out at room temperature
(20–22°C). Cell membrane capacitance was calculated in
each cell throughout the experiment by integrating the
capacitive currents elicited by a ±10 mV voltage pulse.
Currents were detected as inward currents activated on cell
superfusion with the various stimuli in the voltage-clamp
mode at a holding potential of 60 mV. Peak currents acti-
vated in each experimental condition were normalized to cell
membrane capacitance and expressed as mean of the current
density (pA/pF) in averaged results. Signals were sampled at
10 kHz and low-pass filtered at 10 kHz.
Cells and neurons were challenged with isopetasin
(0.1 μM–3 mM), isopetasol (0.1 μM–3 mM) and angelic acid
(Santa Cruz Biotechnology Inc.; TX, USA) (0.1 μM–3 mM) to
assess their ability to promote a cellular response. To induce
TRPA1 channel-dependent responses, cells and neurons were
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challenged with the selective agonist, AITC (1–10 μM).
GSK1016790A (0.05–0.1 μM) was used to induce a selective
response from TRPV4 channel. Buffer solution containing
DMSO 0.5% was used as vehicle. Capsaicin (0.1–1 μM) was
used to induce a selective response of TRPV1 channel and to
identify capsaicin-sensitive neurons. The activating peptide
for human proteinase-activated receptor 2 (hPAR2-AP;
100 μM) or KCl (50 mM) were used to elicit a TRP-
independent cellular response. Some experiments were
performed in the presence of selective antagonists for TRPA1,
HC-030031 (50 μM), for TRPV1, capsazepine (10 μM), for
TRPV4 channels, HC-067047 (30 μM) or their respective
vehicles (0.5, 0.1 and 0.3% DMSO respectively).
Organ bath assays
Contractile response studies were performed on rat orTrpa1+/+
and Trpa1/ mice urinary bladder strips. Briefly, urinary
bladder was excised from rat or mouse and longitudinal strips
were suspended at a resting tension of 1 g for rat and 0.5 g for
mouse tissues in 10 mL organ bath bathed in aerated (95%O2
and 5% CO2) Krebs–Henseleit solution containing (in mM):
119 NaCl, 25 NaHCO3, 1.2 KH2PO4, 1.5 MgSO4, 2.5 CaCl2,
4.7 KCl and 11 D-glucose, maintained at 37°C. After 45 min
of equilibration, tissues were contracted twice with carba-
chol (l μM), with a 45 min washing out period between
the first and second administration. Tissues were challenged
with isopetasin (10–300 μM), AITC (100 μM), GSK1016790A
(10 μM) and capsaicin (0.3 μM) or their vehicles. In some
experiments, tissues were pretreated with the TRPA1 channel
antagonist, HC-030031 (50 μM), the TRPV1 channel antago-
nist, capsazepine (10 μM), the TRPV4 channel antagonist,
HC-067047 (30 μM) or a combination of NK1 and NK2
receptor antagonists, L-733060 and SR48968 respectively,
(both 1 μM). Some tissue preparations were desensitized by
exposure to capsaicin (10 μM for 20 min, twice). Similarly,
some preparations were exposed to isopetasin (100–300 μM
for 20 min, twice) before the challenge with various stimuli.
Motor activity of tissue preparation was recorded isometri-
cally on a force transducer (Harvard Apparatus, Ltd, Kent,
UK). Responses were expressed as percentage (%) of the
maximum contraction induced by carbachol (1 μM).
CGRP-like immunoreactivity (CGRP-LI) assay
For CGRP-LI outflow experiments, 0.4 mm slices of mouse
spinal cord (combined cervical, thoracic and lumbosacral
segments) were superfused with an aerated (95% O2 and 5%
CO2) Krebs–Henseleit solution containing 0.1% bovine se-
rum albumin plus the angiotensin-converting enzyme
inhibitor, captopril (1 μM), and the neutral endopeptidase
inhibitor, phosphoramidon (1 μM), to minimize peptide
degradation. Tissues were stimulated with isopetasin
(10–100 μM) or its vehicle (1% DMSO) dissolved in modified
Krebs–Henseleit solution and superfused for 10 min. Some
tissues were pre-exposed to capsaicin (10 μM, 30 min) or
superfused with a calcium-free buffer containing EDTA
(1 mM). Other tissues were pre-exposed to a high concentra-
tion of isopetasin (300 μM, 30 min) and then, after a
prolonged washing (40 min), stimulated with (100 μM), cap-
saicin (0.3 μM), GSK1016790A (10 μM) or KCl (40 mM). Frac-
tions (4 mL) of superfusate were collected at 10 min intervals
before, during and after administration of the stimulus and
then freeze-dried, reconstituted with assay buffer and
analysed for CGRP-LI by using a commercial enzyme-linked
immunosorbent assay kit (Bertin Pharma, Montigny le
Bretonneux, France). None of the used substances showed
any cross reactivity with the CGRP antiserum. CGRP-LI was
calculated by subtracting the mean prestimulus value from
those obtained during or after stimulation. Detection limits
of the assays were 5 pg·mL1. Results were expressed as
femtomoles of peptide per gram of tissue. Stimuli did not
cross-react with CGRP antiserum.
Behavioural experiments (face rubbing)
For behavioural experiments, after habituation, C57BL/6,
Trpa1+/+ and Trpa1/, Trpv1+/+ and Trpv1/, Trpv4+/+ and
Trpv4/ mice were randomized to treatment groups,
consistent with experimental design. Each experiment was
repeated two to three times (using two or three animals in
each experimental session). For the in vivo experiments, the
first outcome assessed was acute spontaneous nociception
evoked by the s.c. injection (10 μL), into the right mouse
whisker pad (perinasal area), of AITC (10–100 nmol),
capsaicin (0.5–3 nmol), GSK1016790A (1–5 nmol), isopetasin
(5–50 nmol) or their vehicle (2.5% DMSO). Nociception was
assessed by measuring the time (seconds) that the animal
spent rubbing the injected area of the face with its paws
(Luccarini et al., 2006). These observations were made
without knowledge of the treatments given (blinded). The
nociceptive effects of s.c. injection (10 μL) of isopetasin
(50 nmol) and AITC (50 nmol) or capsaicin (3 nmol) or
GSK1016790A (2.5 nmol) were also tested in Trpa1+/+ and
Trpa1/, Trpv1+/+ or Trpv1/, Trpv4+/+ or Trpv4/mice re-
spectively. To assess the pharmacological target of isopetasin,
C57BL/6 mice received isopetasin (50 nmol in 10 μL, s.c.)
60 min after i.p. treatment with the selective TRPA1 channel
antagonist, HC-030031 (100 mg·kg1) or 30 min after the se-
lective TRPV1 channel antagonist, capsazepine (4 mg·kg1)
or 60 min after the selective TRPV4 channel antagonist,
HC-067047 (100 mg·kg1) or their vehicle (4% DMSO plus
4% tween 80 in isotonic saline).
Then, the preventive effect of isopetasin on nociceptive
responses evoked by known TRPA1, TRPV1 and TRPV4
channel agonists was measured. Isopetasin (5 mg·kg1) was
administered i.g. quod diem (q.d.) for 5 days in C57BL/6 or
Trpa1/ mice and each day, 60 min later, AITC (50 nmol) or
capsaicin (3 nmol) or GSK1016790A (2.5 nmol) or their
vehicle were injected (10 μL, s.c.) and behavioural tests
performed, as described above. The dose of isopetasin for
preventive purposes was calculated according to the
National Institute of Health conversion formula in order
to administer to animals a dose similar to that has been
proved efficacious for migraine prevention in humans
(Reagan-Shaw et al., 2008).
Dural blood flow
Rats were anesthetized (urethane, 1.4 g in 10 mL·kg1, i.p.),
and the head fixed in a stereotaxic frame. A cranial window
(4 × 6 mm) was opened into the parietal bone to expose the
dura mater. Changes in rat middle meningeal artery blood
flow were recorded with a Laser Doppler Flowmeter (Perimed
Instruments, Milan, Italy). The probe (needle type, tip
diameter 0.8 mm) was fixed near a branch of the middle
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meningeal artery (1 mm from the dural outer layer). The win-
dow was filled with synthetic interstitial fluid. In a first set of
experiments, dural blood flowwasmonitored for 30min after
administration of isopetasin (5 mg in 10 mL·kg1, i.p.) or its
vehicle. In a second set of experiments, dural blood flow
was measured after the administration of acrolein (50 nmol,
intranasal), ethanol (140 μL·kg1, i.v.), sodium nitroprusside
(1 mM, 100 μL, topical to the exposed dura mater) or their
vehicles (isotonic saline) in rats treated for 5 days with
isopetasin (5 mg·kg1, i.g.) or its vehicle 60 min after the
treatment. Baseline flow was calculated by the mean flow
value measured during a 5 min period prior to stimulus.
The increase in blood flow was calculated as change (%)
over the baseline.
Data and statistical analysis
The data and statistical analysis in this study comply with
the recommendations on experimental design and analysis
in pharmacology (Curtis et al., 2015). Data are reported as
mean ± SEM. Statistical analysis was performed by the un-
paired two-tailed Student’s t-test for comparisons between
two groups and the ANOVA, followed by the Bonferroni
post hoc test, for comparisons between multiple groups
(GraphPadPrism version 5.00, San Diego, CA, USA). Agonist
potency was expressed as the EC50. P < 0.05 was considered
statistically significant.
Materials
1H (500 and 400MHz) NMR spectra were measured on Varian
INOVA NMR spectrometers (Palo Alto, CA, USA). Chemical
shifts were referenced to the residual solvent signal (CDCl3:
δH = 7.26). Silica gel 60 (70–230 mesh) used for gravity col-
umn chromatography was purchased from Macherey-Nagel
(Düren, Germany). Reactions were monitored by TLC on
Merck 60 F254 (0.25 mm) plates (Kenilworth, NJ, USA), visu-
alized by staining with 5% H2SO4 in methanol and heating.
Organic phases were dried with Na2SO4 before evaporation.
Chemical reagents and solvents were from Sigma-Aldrich
(Milan, Italy) and were used without any further purification
unless stated otherwise. All natural compounds were finally
purified with Jasco-HPLC, Hichrom column 21.2 × 250 mm
(Tokyo, Japan), normal phase with PU-2080 binary pump
and UV-2075 plus detector to guarantee a purification degree
for biological assays.
For petasin isolation, a sample (500 g) of common
butterbur [P. hybridus (L.) Gaertn.] roots collected in the Swiss
Alps was powdered using a kitchen blender. The root powder
was extracted twice with 5 L of acetone (ratio plant:solvent
1:10), affording, after filtration and evaporation, 14.36 g
(2.9%) of a dark brown oily extract. The latter was purified
by gravity column chromatography on silica gel using petro-
leum ether-EtOAc (from 9:1 to 7:3) as eluant to afford 9 g
(1.8%) of petasin as yellow oil, identified by comparison with
spectroscopic data. For isomerization of petasin to isopetasin,
500 mg of NaH 95% (36.53 mmol) was added to a solution of
petasin (390 mg, 1.23 mmol) in toluene (10 mL). After stir-
ring for 20 h at room temperature, the reaction was quenched
by dilution with water; 2NH2SO4 was added, and the reaction
was extracted with ethyl acetate. The organic phase was dried,
filtered and evaporated. The residue, a brown oil, was purified
by gravity column chromatography on silica gel using
petroleum ether-EtOAc (9:1) as eluant and further purified
with HPLC to yield 256 mg (65.6%) of isopetasin (1b) as yel-
low oil. The hydrolysis of petasin in isopetasol has been ob-
tained by adding petasin (350 mg, 1.10 mmol) to a 5% KOH
methanol (10 mL) solution. After stirring for 20 h at room
temperature, the reaction was diluted with 2N H2SO4 and ex-
tracted with EtOAc. The organic phase was dried, filtered and
evaporated. The residue, a brown oil, was purified by gravity
CC on silica gel using petroleum-ether (5:5) as eluant and fur-
ther purified with HPLC to yield 187.7 mg (72.8%) of
isopetasol as white crystals.
For in vitro experiments, isopetasin and isopetasol were
dissolved in 100% DMSO at 10 mM concentration and then
diluted in aqueous solution. For systemic in vivo treatment,
isopetasin (5 mg in 10 mL·kg1) was dissolved in 0.5% car-
boxymethylcellulose solution (CMC) for intragastric (i.g.)
administration or in 4% DMSO plus 4% tween 80 in
isotonic saline for i.p. administration. HC-030031 was
synthesized as previously described (Andre et al., 2008). If
not otherwise indicated, all other reagents were from
Sigma-Aldrich (Milan, Italy) and dissolved in appropriate
vehicle solutions.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY (Southan
et al., 2016), and are permanently archived in the Concise
Guide to PHARMACOLOGY 2015/16 (Alexander et al.,
2015a,b).
Results
Isopetasin targets the human TRPA1 channel
In hTRPA1-HEK293 cells, isopetasin and isopetasol, but not
angelic acid, produced concentration-dependent increases
in [Ca2+]i (EC50s 10 and 100 μM respectively), responses that
were attenuated by the selective TRPA1 channel antagonist,
HC-030031 (Figure 1A and Supporting Information Figure
S1C). hTRPV1-HEK293 and hTRPV4-HEK293 cells that were
activated by capsaicin or GSK1016790A (TRPV1 and TRPV4
channel agonists respectively) did not respond to isopetasin
(Figure 1C, D). In whole-cell patch-clamp recordings,
isopetasin elicited inward currents in hTRPA1-HEK293 cells
that were abolished by HC-030031 (Figure 1B). Isopetasin
did not evoke any current in hTRPV1-HEK293 and hTRPV4-
HEK293 cells (Figure 1C, D). Isopetasin and isopetasol did
not induce any cellular response in naïve HEK293 cells
(Supporting Information Figure S1B, D). 3C/K-Q hTRPA1-
HEK293 cells, which express a TRPA1 which lacks three
cysteine and one lysine residues, responded to the non-
electrophilic agonist, menthol, as wild-type hTRPA1-
HEK293, but failed to respond to isopetasin (50 μM)
(Figure 1E). In IMR90, which constitutively express the
TRPA1 channel (Jaquemar et al., 1999), isopetasin
concentration-dependently increased [Ca2+]i, (EC50 8 μM), a
response that was abolished by HC-030031 (Figure 1F and
Supporting Information Figure S1E). Calcium responses
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elicited by hPAR2-AP and ion currents evoked by KCl were
not affected by HC-030031 indicating selectivity (Figure 1A,
B, F and Supporting Information Figure S1B–D).
Isopetasin selectively activates the rodent and
human TRPA1 channel
Exposure of cultures of rat TG neurons to isopetasin
evoked a concentration-dependent (EC50 10 μM) [Ca
2+]i
increase in neurons that responded to capsaicin (Figure 2A
and Supporting Information Figure S1F). Responses to
isopetasin were abolished by HC-030031, but not by
selective TRPV1 (capsazepine) or TRPV4 channel (HC-
067047) antagonists (Figure 2A). Notably, while isopetasin,
AITC and capsaicin activated TG neurons from Trpa1+/+
mice, neurons from Trpa1/ mice responded only to
capsaicin (Figure 2C). In capsaicin-sensitive rat TG
Figure 1
Isopetasin (isoPET) selectively activates the human TRPA1 channels. (A) Representative traces and pooled data of the [Ca2+]i response evoked by
isoPET (50 μM) in HEK293 cells transfected with the cDNA of human TRPA1 (hTRPA1-HEK293). [Ca2+]i response evoked by isoPET (50 μM) and the
selective TRPA1 channel agonist, AITC (10 μM) are abolished by the selective TRPA1 channel antagonist, HC-030031 (HC03; 30 μM), which does
not affect the response evoked by the activating peptide for hPAR2 (hPAR2-AP (100 μM). (B) Representative traces and pooled data of the whole-
cell patch-clamp inward currents evoked by isoPET (10 μM), AITC (100 μM) and KCl (60 mM) in hTRPA1-HEK293. HC03 abates the response to
both isoPET and AITC without affecting the KCl response. (C, D) Representative traces of [Ca2+]i responses and whole-cell patch-clamp inward
currents in HEK293 cells transfected with the cDNA of human TRPV1 (hTRPV1-HEK293) (C) or with the cDNA of human TRPV4 (hTRPV4-
HEK293) (D) show that isoPET (50 μM in [Ca2+]i imaging or 10 μM in electrophysiological experiments) does not activate either TRPV1 or TRPV4
channels, which are activated by their respective agonist, capsaicin (CPS; 1 μM) and GSK1016790A (GSK101; 100 nM) respectively. (E) Pooled
data of [Ca2+]i responses evoked by isoPET (100 μM) and menthol (300 μM) in wild-type (wt) and mutant (3C/K-Q) hTRPA1-HEK293 transfected
cells. (F) Representative traces and pooled-data of [Ca2+]i response induced by isoPET in IMR90. HC03 inhibits the [Ca
2+]i response activated by
isoPET (50 μM) but not that evoked by hPAR2-AP (100 μM). Veh is the vehicle of isoPET. Each column represents the mean ± SEM of n > 25 cells
from three to six independent experiments for [Ca2+]i recording or n> 5 cells from four to eight independent experiments for electrophysiological
recording. Dash indicates combined vehicles of treatments. *P < 0.05, significantly different from veh, §P < 0.05, significantly different from
isoPET; ANOVA followed by Bonferroni test.
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neurons, isopetasin evoked inward currents that were selec-
tively blocked by HC-030031 but unaffected by
capsazepine and HC-067047 (Figure 2B). Thus, calcium
and electrophysiology data indicated that TRPA1 channel
are necessary and sufficient for rodent nociceptors and
human cells to respond to isopetasin.
Figure 2
Isopetasin (isoPET) selectively activates TRPA1 channel in cultures of rodent TG neurons. (A, B) Representative traces and pooled data of [Ca2+]i
responses (A) and whole-cell patch-clamp inward currents (B) evoked by isoPET (50 μM) in rat TG neurons responding to capsaicin [CPS;
0.1 μM (A) and 1 μM (B)]. Both [Ca2+]i responses and ion currents elicited by isoPET are abolished in the presence of the selective TRPA1 channel
antagonist, HC-030031 [HC03; 30 μM (A) and 50 μM (B)], and unaffected in the presence of the selective antagonist for TRPV1 channels,
capsazepine (CPZ; 10 μM), or TRPV4 channels, HC-067047 (HC06; 30 μM). (C) Representative traces and pooled data of the [Ca2+]i response
evoked by isoPET (50 μM) or AITC (30 μM) in cultured TG neurons from Trpa1+/+ mice; both responses are absent in neurons from Trpa1/mice.
Responses to capsaicin (CPS; 0.1 μM) are unchanged. Veh is the vehicle of isoPET. Each column represents the mean ± SEM of n> 20 neurons from
three to six independent experiments for [Ca2+]i recordings or of at least n > 5 cells from four to eight independent experiments for electrophys-
iological recordings. Dash indicates combined vehicles of treatments. *P < 0.05, significantly different from veh, §P < 0.05, significantly different
from isoPET; ANOVA followed by Bonferroni test.
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Isopetasin excites and desensitizes rodent
peptidergic nociceptors
In cultured rat TG neurons, currents evoked by AITC or capsa-
icin were unaffected by pre-exposure to AITC but were mark-
edly desensitized after pre-exposure to isopetasin at high
(50 μM), but not at low concentration (5 μM) (Figure 3A).
Isopetasin-evoked CGRP release from mouse dorsal spinal
cord slices was abolished in tissues desensitized to capsaicin
or in the absence of extracellular Ca2+ (Figure 3D), indicating
that isopetasin evokes a neurosecretory process from neurons
expressing TRPV1 channel. The role of TRPA1 channel in
neuronal excitation and the ensuing neurosecretion by
isopetasin was demonstrated by its failure to evoke any
release in spinal cord slices from Trpa1/ mice (Figure 3E).
Notably, exposure to an elevated concentration of isopetasin
attenuated the release of CGRP produced by AITC, capsaicin
and the non-specific depolarizing agent KCl (Figure 3F),
indicating heterologous neuronal desensitization.
Terminals of peptidergic primary sensory neurons are
widely expressed in most tissues and organs. The rodent uri-
nary bladder contains a dense network of SP-containing nerve
fibres, whose stimulation results in SP release from intramural
sensory nerve endings that viaNK1/NK2 receptor stimulation
contracts the bladder smooth muscle (Steinhoff et al., 2014).
Figure 3
Isopetasin (isoPET) elicits characteristic desensitization of TRPA1 channel. (A) Representative traces and pooled data of whole-cell patch-clamp
inward currents through rat TG neurons showing that the initial challenge with isoPET (50 μM), instead of AITC (100 μM), or its vehicle (veh),
produces neuronal desensitization with a reduced response to the subsequent exposure to AITC (100 μM) and capsaicin (CPS; 1 μM). Each
column represents the mean ± SEM of n > 6 independent experiments. (B) Concentration–response curve of the contractile response evoked
by AITC and isoPET in rat urinary bladder strips. At the highest concentration used, isoPET (300 μM) evokes a contractile response that is selectively
inhibited by the selective TRPA1 channel antagonist HC-030031 (HC03; 50 μM) and unaffected by the selective TRPV1 channel antagonist
capsazepine (CPZ; 10 μM) or the selective TRPV4 channel antagonist, HC-067047 (HC06; 30 μM). The isoPET contraction is also abolished by
a combination of NK1 and NK2 receptor antagonists (NK1/2 RA; L-733060 and SR48968, both 1 μM) and after exposure (20 min, twice) to a high
concentration of capsaicin (CPS; 10 μM) that induces neuronal desensitization. (C) Exposure (20 min, twice) to the highest concentration of
isoPET (300 μM) markedly reduces the contractile response evoked by a selective TRPA1, TRPV4 or TRPV1 channel agonist, AITC (100 μM),
GSK1016790A (GSK101; 10 μM) or CPS (0.3 μM), but does not affect the response to carbachol (Cch; 1 μM). (D) isoPET increases the CGRP-LI
outflow from mouse dorsal spinal cord slices in a concentration-dependent manner. Effect of isoPET (100 μM) is abolished by calcium removal
(Ca2+-free), capsaicin desensitization (CPS-des). (E) isoPET (100 μM) increases CGRP-LI outflow from spinal cord slices from Trpa1+/+ mice, but
not from Trpa1/ mice. (F) Exposure to a high concentration of isoPET (300 μM, 30 min) blocks CGRP-LI release evoked by AITC (50 μM),
GSK101 (10 μM), CPS (0.3 μM) or KCl (40 mM). Each column represents the mean ± SEM of n = 4 independent experiments. Dash indicates
combined vehicles of the treatments. *P < 0.05, significantly different from veh; §P < 0.05, significantly different from isoPET; ANOVA followed
by Bonferroni test. #P < 0.05, significantly different from isoPET, Student’s t-test.
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Isopetasin caused a concentration-dependent contraction of
isolated strips of the rat urinary bladder, a response attenuated
by desensitization to capsaicin, NK1 and NK2 receptor
(L-733060 and SR48968 respectively) antagonism and HC-
030031, but not by capsazepine or HC-067047 (Figure 3B).
In addition, isopetasin induced contractile responses in iso-
lated strips of urinary bladders obtained from Trpa1+/+ mice,
but not in those obtained from Trpa1/ mice (Supporting
Information Figure S2A). Thus, isopetasin-evoked contrac-
tions were the result of SP release from peptidergic sensory
nerve terminals, through activation of TRPA1 channels. Ex-
posure of urinary bladder strips to a high concentration of
isopetasin markedly attenuated contractions evoked by AITC
and capsaicin, but not by carbachol, suggesting neuronal de-
sensitization that, however, preserved the contractility of
the bladder smooth muscle (Figure 3C). Furthermore, expo-
sure to a high isopetasin concentration attenuated the con-
tractile response to capsaicin in isolated strips of urinary
bladders obtained from Trpa1+/+ mice, but not in those
obtained from Trpa1/mice (Supporting Information Figure
S2B), suggesting that isopetasin induces neuronal desensitiza-
tion by selective targeting of TRPA1 channels.
Isopetasin inhibits nociception and neurogenic
dural vasodilatation via TRPA1 channel
Subcutaneous injection of irritant agents into the upper
whisker pad of mice produces a typical nocifensor behaviour
described as facial rubbing (Luccarini et al., 2006). Injection
(s.c.) of AITC into the upper whisker pad evoked a transient
(<15 min) and dose-dependent facial rubbing that was
abolished by HC-030031 (Figure 4A). Similarly, facial rubbing
produced by capsaicin was attenuated by capsazepine
(Figure 4B), while facial rubbing evoked by GSK1016790A
was inhibited by the TRPV4 channel antagonist, HC-067047
(Figure 4C). Isopetasin produced facial rubbing that
reproduced the features of the response to AITC, being
abolished by HC-030031 and unaffected by capsazepine or
HC-067047 (Figure 4D). Moreover, similar to AITC, isopetasin
failed to provoke any facial rubbing in Trpa1/ mice
(Figure 4E). Isopetasin-evoked facial rubbing in Trpv1/ and
Trpv4/mice was similar to that observed in their respective
wild-type littermates (Figure 4F).
A single dose of isopetasin (given i.g.) did not affect the
ability of local AITC, capsaicin or GSK1016790A to evoke fa-
cial rubbing (Figure 5A). However, after giving a single dose
of isopetasin for three consecutive days, rubbing responses
to AITC and GSK1016790A were reduced, whereas that to
capsaicin was unaffected (Figure 5A). Following isopetasin
administration for five consecutive days, responses to AITC,
GSK1016790A and capsaicin were further attenuated
(Figure 5A). This indicates that longer-term repeated
isopetasin i.g. administration leads to a desensitization of
nocifensive behaviour specifically evoked by activators of
TRPV1, TRPV4 and TRPA1 channels. Moreover, chronic
administration of isopetasin for five consecutive days in
Trpa1/ mice did not affect facial rubbing evoked by
TRPV1 or TRPV4 channel agonists (Supporting
Information Figure S2C). These in vivo results support the hy-
pothesis, originated by in vitro findings, that desensitization
to isopetasin requires selective targeting of the TRPA1
channel. With more direct relevance for headaches and mi-
graine, we next intended to test whether this would also af-
fect CGRP-mediated dilation of meningeal arteries, which
we subsequently assessed in rats. Firstly, i.p. administration
of isopetasin did not produce any detectable change in men-
ingeal perfusion (Supporting Information Figure S2D). Sec-
ondly, after isopetasin administrations for five consecutive
days, increases in blood flow produced by the TRPA1 channel
agonist, acrolein (Bautista et al., 2006; Kunkler et al., 2011),
and the TRPV1 channel agonist, ethanol (Nicoletti et al.,
2008; Trevisani et al., 2002), were reduced (Figure 5B). In con-
trast, the response to the direct vasodilator sodium nitroprus-
side remained unchanged (Figure 5B).
Discussion
Pharmacological and genetic data presented here show that
isopetasin activates the universal irritant receptor ion chan-
nel, TRPA1. Mouse, rat and human (native and recombinant)
TRPA1 channels are gated with similar efficacy and potency
by isopetasin, suggesting that responses evoked by the drug
in vivo in rodents could be reproduced in humans. Further-
more, failure to activate TRPV1 and TRPV4 channels indi-
cates that nociceptor activation by isopetasin is caused by
selective targeting of TRPA1 channels. As isopetasin failed to
evoke calcium responses in the mutant transfected cells
(3C/K-Q hTRPA1-HEK293), the molecular mechanism
responsible for channel activation by this compound must
be similar to that proposed for electrophilic and reactive
agonists that gate TRPA1 channel via the involvement of
specific cysteine/lysine residues (Hinman et al., 2006; Trevisani
et al., 2007). Moreover, isopetasol, but not angelic acid, induced
a calcium response in cells expressing TRPA1 channel. Thus, the
hemiterpene moiety of angelic acid is not critical for activity,
while the eremophilane sesquiterpenoid framework of
isopetasol is essential for channel gating.
Peripheral sensory neurons expressing TRPA1 channel
exert a dual function in as much as they both signal nocicep-
tive stimuli to the brain and, by releasing the neuropeptides
SP and CGRP, mediate neurogenic inflammation responses
in the vasculature and other organs (Benemei et al., 2014;
Nassini et al., 2014). In the rat urinary bladder, AITC, by
targeting TRPA1 channel on intramural nerve terminals,
elicits neurogenic SP-mediated smooth muscle contractions
(Andrade et al., 2006). Isopetasin produced an effect similar
to that of AITC in terms of mechanism of action. However,
the efficacy of isopetasin was much lower than that of AITC,
indicating that the herbal compound may act as a partial ag-
onist of the channel. Isopetasin, similarly to parthenolide
(Materazzi et al., 2013), caused desensitization of peptidergic
primary sensory neurons either limited to TRPA1 channel,
or involving other TRP channel stimulants and non-TRP
depolarizing agents. Transition from homologous to heterol-
ogous desensitization seems to depend on the concentration
and time of exposure to isopetasin. Pre-exposure to isopetasin
of cultured TG neurons or their central terminals in the dorsal
brainstem reduced AITC-evoked currents or CGRP release re-
spectively. Desensitization of sensory nerve terminals by
isopetasin was not limited to trigeminal innervation, as it
was observed in nerve terminals of the rat urinary bladder.
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Figure 4
Local administration of isopetasin (isoPET) evokes irritant pain. (A) Time course of facial-rubbing in C57BL/6 mice after s.c.injection (10 μL) of the
selective TRPA1 agonist, AITC (50 nmol) or its vehicle (veh) into the whisker pad. Time that mice spent rubbing is plotted for each 5min block over
25 min. The irritant pain evoked by AITC, quantified as the total time spent rubbing in the first 10 min, is dose-dependent and abolished in mice
pretreated with the selective TRPA1 antagonist HC-030031 (HC03; 100 mg·kg1 i.p., 1 h before). Similar to AITC, s.c. injection of (B) the selective
TRPV1 agonist, capsaicin (CPS) or (C) the selective TRPV4 channel agonist, GSK1016790A (GSK101), shows dose-dependent irritant pain behav-
iours which are blocked by pretreatment with their respective antagonist, capsazepine (CPZ; 4mg·kg1, i.p. 30min before) or HC-067047 (HC06;
10 mg·kg1, i.p., 30 min before). (D) Local injection (10 μL, s.c.) of isoPET into the whisker pad of C57BL/6 mice elicits dose-dependent irritant
behaviours. The effect evoked by isoPET (50 nmol) was blocked in mice pretreated with HC03 but unaffected in HC06 or CPZ pretreated mice. (E)
Time course of the facial-rubbing activity evoked by both AITC (50 nmol in 10 μL, s.c.) and isoPET (50 nmol in 10 μL, s.c.), or their respective veh in
Trpa1+/+ mice. No effect is observed in injected Trpa1/ mice. (F) isoPET injection (50 nmol in 10 μL, s.c.) into the whisker pad of Trpv1+/+ and
Trpv1/mice elicits a similar irritant effect, while CPS (3 nmol in 10 μL, s.c.) produces an irritant response only in Trpv1+/+mice. Similarly, Trpv4+/+
and Trpv4/ show a similar irritant response to isoPET, while GSK101 (2.5 nmol in 10 μL, s.c.) produces an irritant response only in Trpv4+/+mice.
Values are mean ± SEM of at least five mice from three independent experiments. *P < 0.05, significantly different from veh or veh Trpa1+/+ or veh
Trpv1+/+ or veh Trpv4+/+, §P < 0.05 significantly different from AITC or CPS or GSK101 or isoPET or CPS Trpv1+/+ or GSK101 Trpv4+/+, ANOVA
followed by Bonferroni test or Student’s t-test.
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In this preparation, neurogenic SP-mediated smooth muscle
contractions evoked by AITC and capsaicin (Andrade et al.,
2006) were markedly reduced by pre-exposure to isopetasin.
Inhibition of neurogenic inflammation by isopetasin in
extra-trigeminal innervation may help explain the reported
beneficial effects of butterbur in painful and inflammatory
conditions, such as arthritis (Arnold et al., 2015) and allergic
rhinitis (Lee et al., 2003; Schapowal, 2002).
Data obtained in vitro were reproduced in vivo. The facial
rubbing evoked by s.c. AITC was characterized as an effect
mediated by TRPA1 channel, while capsaicin or
GSK1016790A were effective via TRPV1 or TRPV4 channels
respectively. To mimic the clinical use of butterbur in mi-
graine treatment, isopetasin was given via i.g. administration.
Results showed a time-dependent increase in the
desensitizing effect of i.g. isopetasin that initially involved
only TRPA1 channel but, later, involved TRPV4 and TRPV1
channels. Thus, after a single isopetasin dose, the rubbing
responses to AITC, capsaicin and GSK1016790A were unaf-
fected, significant inhibition of AITC- or GSK1016790A-
mediated responses was observed following a 3 day cycle of
isopetasin administration. After a 5 day cycle, the capsaicin-
mediated nociceptive response was also attenuated. This
finding suggests that a more prolonged treatment schedule,
providing a non-selective (heterologous) desensitization of
peptidergic nerve terminals with TRPV1/TRPA1/TRPV4
channels, might be beneficial in migraine prophylaxis.
The molecular bases of the process that results in channel
and neuronal desensitization have been investigated more
extensively following activation of TRPV1 channel. Exposure
to capsaicin or resiniferatoxin results in a time- and
concentration-dependent massive Ca2+ influx into the
neurons that results in a neurotoxic cation overload, thus
attenuating nociceptor functioning. Although neuronal
desensitization produced by TRPA1 channel has been
explored in less detail, the AITC-evoked heterologous
desensitization of CGRP release from the rat hind paw skin
is Ca2+-dependent, similar to that produced by capsaicin
(Ruparel et al., 2008). Furthermore, in meningeal afferents,
selective stimulation of TRPA1 channel increased activation
threshold and promoted CGRP release but did not cause
propagated action potentials, suggesting that co-expression
of TRPV1 channel in peripheral nociceptors is required for
TRPA1-mediated pro-nociceptive function (Denner et al.,
2017). Our present experiments do not contradict this
proposal because, as indicated by desensitization studies,
isopetasin-evoked responses (bladder contraction, rubbing
behaviour, CGRP release and increase in dural blood flow)
were all mediated by TRPA1 channel apparently expressed
in TRPV1-positive primary afferents.
Figure 5
Chronic administration of isopetasin (isoPET) desensitizes sensory nerve endings. (A) Daily i.g. administration of isoPET (5 mg·kg1) in naïve
C57BL/6 mice gradually reduces the nociceptive response evoked by s.c. injection (10 μL) of AITC (10 nmol), capsaicin (CPS; 3 nmol) or
GSK1016790A (GSK101; 2.5 nmol) in mouse whisker pad and measured as the facial-rubbing activity observed in the first 15 min after the injec-
tion. Veh is the vehicle of the various stimuli. Values are mean ± SEM of at least fivemice per group from three independent experiments. *P< 0.05,
significantly different from veh, §P < 0.05, significantly different from veh-isoPET, ANOVA followed by Bonferroni test. (B) Representative traces
and pooled data of the increases in dural blood flow evoked by intranasal acrolein (ACR, 50 nmol in 50 μL), intravenous ethanol (EtOH,
140 μL·kg1) or dural application (100 μL) of sodium nitroprusside (SNP; 10 mM) in rat treated for 5 days with systemic isoPET (5 mg·kg1, i.g.
per day) or its vehicle (0.5% CMC 10 mL·kg1, i.g. per day). Chronic treatment with isoPET significantly reduced responses to ACR and EtOH,
but not to SNP. Values are mean ± SEM of at least five rats per group from three independent experiments. #P < 0.05, significantly different from
veh-isoPET; Student’s t-test.
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Clinical studies with lowMW compounds that selectively
block the CGRP receptor for the acute and preventive treat-
ment of the migraine attack (Edvinsson, 2015a; Ho et al.,
2008; Olesen et al., 2004) or, more recently, with anti-CGRP
monoclonal antibodies as preventive anti-migraine medi-
cines (Bigal et al., 2015), have strengthened the hypothesis
of a pivotal role of this neuropeptide in themechanism of mi-
graine headaches. Although the precise CGRP-dependent
pathway that results in the pain and associated symptoms
of migraine attack has not been completely identified,
peptidergic neurons of the trigeminal ganglion appear to play
a major role in migraine pain (Edvinsson, 2015a). CGRP re-
leased from sensory nerve terminals in rodents and other
mammals, including humans, dilates arterial vessels (Sinclair
et al., 2010), including meningeal arteries (Dux et al., 2016;
Kunkler et al., 2011; Nicoletti et al., 2008). Thus, CGRP-
mediated meningeal vasodilatation following stimulation of
TG neurons is considered a good approximation of the neuro-
chemical events that occur during the migraine attack. Previ-
ous studies have shown that meningeal vasodilation evoked
by administration of either acrolein (intranasal) or ethanol
(i.p.) is mediated by CGRP released from perivascular trigem-
inal nerve endings triggered by activation of TRPA1 or TRPV1
channels respectively (Kunkler et al., 2011; Nicoletti et al.,
2008). The present observation that 5 days of isopetasin,
given i.g., attenuated the increase in rat dural blood flow
evoked by both acrolein and ethanol suggests that isopetasin,
possibly by targeting TRPA1 channels, desensitized trigemi-
nal nociceptors so they were no longer able to release the mi-
graine mediator, CGRP. This novel property of isopetasin
may add to the mechanisms previously described (Ko et al.,
2001; Thomet et al., 2001; Wang et al., 2001; Wang et al.,
2002) to explain the action of chronically administered
butterbur to preventmigraine (Grossmann and Schmidramsl,
2000; Lipton et al., 2004; Pothmann and Danesch, 2005).
Migraine therapy consists of different classes of drugs.
While acute treatment of attacks is confined to analgesics,
non-steroidal antiinflammatory drugs and triptans, the
prevention of attacks is primarily based on β-blockers, anti-
epileptics, anti-depressants and 5-HT antagonists. It is
possible that in the near future, low MW CGRP receptor an-
tagonists (gepants) will be used for acute treatment and
anti-CGRP or anti-CGRP receptor monoclonal antibodies will
be used for prophylaxis. Our present findings support the
view that some drugs and herbal medicines currently pre-
scribed for the acute or prophylactic treatment of migraine
can be grouped into a novel class of therapeutics, namely,
TRPA1 channel inhibitors. These comprise compounds that
target the channel with different modalities. The universally
used acetaminophen (paracetamol) via its reactive metabo-
lite, N-acetylbenzoquinoneimine, activates (Nassini et al.,
2010) and then desensitizes (Andersson et al., 2011) TRPA1
channel. The well-established, but still widely and success-
fully prescribed pyrazolone derivatives (Ramacciotti et al.,
2007), dipyrone (metamizole) (Bigal et al., 2002) and
propyphenazone, are selective TRPA1 channel antagonists
(Nassini et al., 2015). The active component of feverfew,
parthenolide, moderately stimulates TRPA1 channel both
in vitro and in vivo, causing channel desensitization and
neuronal dysfunction (Materazzi et al., 2013). Butterbur is
indicated as per the American Headache Society guidelines
with a level A recommendation for migraine prophylaxis
(Holland et al., 2012). The present findings would add the
butterbur constituent, isopetasin (Aydin et al., 2013), to the
list of TRPA1-tropic agents, which, like parthenolide, stimu-
late the channel, thereby causing desensitization of
peptidergic trigeminal nerve terminals, attenuating their
ability to release CGRP and to signal pain. Successful treat-
ment and prevention of migraine by targeting of TRPA1 cat-
ion channels and the ensuing peptidergic sensory neuron
dysfunction by parthenolide and isopetasin provides a solid
basis for future basic and translational investigations of
migraine treatments based on actions at TRPA1 channels.
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Figure S1 (A) Chemical structures of isopetasol, angelic acid
and isopetasin (isoPET). (B) Challenge with isoPET (50 μM)
does not elicit calcium responses or ion currents in
untransfected HEK293 cells which instead responded to the
activating peptide for human proteinase activated receptor
2 (hPAR2-AP, 100 μM) or KCl (100 μM). (C) Representative
traces, concentration–response curve and pooled data of the
calcium response evoked by isopetasol in HEK293 cells
transfected with the cDNA coding for human TRPA1 chan-
nels (hTRPA1-HEK293). isoPET induces a similar
concentration–response curve in hTRPA1-HEK293 cells with
a higher maximum effect at the highest concentration used.
Angelic acid does not produce calcium response at any of
the concentrations tested (0.5 μM – 3 mM). The calcium re-
sponse evoked by isopetasol (100 μM) is abolished in the pres-
ence of the selective TRPA1 channel antagonist HC-030031
(HC03; 30 μM) and is absent in (D) untransfected HEK293
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cells. Concentration–response curves of the calcium response
evoked by isoPET in human fetal lung fibroblasts, IMR90 (E),
and in rat cultured trigeminal ganglion (TG) neurons (F). Veh
is the vehicle of isopetasol. Each column or point represents
the mean ± SEM of n > 20 cells or neurons from 3–6 indepen-
dent experiments. Dash indicates vehicle of HC03. *P < 0.05
vs. veh, §P < 0.05 vs. isopetasol; ANOVA followed by
Bonferroni test.
Figure S2 (A) Isopetasin (isoPET; 300 μM) evokes a contrac-
tile response in strips of mouse urinary bladder isolated form
Trpa1+/+ mice, an effect that is absent in urinary bladder from
Trpa1/mice. (B) Exposure (20 min, twice) to a high concen-
tration of isoPET (300 μM) markedly reduces the contractile
response evoked by the selective TRPV1 channel agonist, cap-
saicin (CPS; 0.3 μM), in longitudinal strips of mouse urinary
bladder isolated from Trpa1+/+ mice, but not in tissues from
Trpa1/mice. isoPET (300 μM) does not affect the contrac-
tile response to carbachol (CCh; 1 μM) in either Trpa1+/+ or
Trpa1/ mouse urinary bladders. Each column represents
the mean ± SEM of n = 5 from 3 independent experiments.
Veh is the vehicle of isoPET. *P < 0.05 vs. Trpa1+/+ veh or
Trpa1+/+ veh isoPET; ANOVA followed by Bonferroni test.
(C) In Trpa1/ mice daily intragastric (i.g.) administration
of isoPET (5 mg·kg1) does not affect nociceptive response
elicited by s.c. injection (10 μL) of capsaicin (CPS; 3 nmol)
or GSK1016790A (GSK101; 2.5 nmol) into mouse whisker
pad and measured as the facial-rubbing activity observed in
the first 15 min after injection. Veh is the vehicle of the vari-
ous stimuli. Values are mean ± SEM of at least 4 mice per
group from 3 independent experiments. *P < 0.05 vs. veh,
ANOVA followed by Bonferroni test. (D) Representative trace
of the effect in rat dural blood flow evoked by intraperitoneal
isoPET (5 mg·kg1), intranasal acrolein (ACR, 50 nmol in
50 μL), intravenous ethanol (EtOH, 140 μL·kg1) or dural ap-
plication (100 μL) of sodium nitroprusside (SNP; 10 mM,).
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